Menest Shortage: What Providers and Prescribers Need to Know in 2026

If patients have been calling your office about difficulty filling their Menest (esterified estrogens) prescriptions, this briefing provides the clinical context, therapeutic alternatives, and patient management strategies you need for 2026.

Current Shortage Status

As of early 2026, esterified estrogens (Menest) are not formally listed on the FDA drug shortage database. However, real-world availability has been intermittent and regionally inconsistent due to multiple compounding factors:

Demand surge: Estrogen prescriptions for women aged 45–54 increased 184% between 2018 and 2026 (Truveta data), with a further 20% surge between July 2025 and February 2026

FDA labeling change: In November 2025, the FDA initiated removal of black box warnings for cardiovascular disease, breast cancer, and probable dementia from menopausal HRT products — contributing to increased prescribing

Patch shortage spillover: A widespread shortage of estradiol patches (affecting all major brands including Climara, Vivelle-Dot, and generics from Teva and Mylan) expected to continue through end of 2026 is driving patients toward oral estrogen alternatives

Manufacturing concentration: Only a small number of manufacturers produce generic esterified estrogen tablets; Pfizer discontinued the 2.5 mg Menest strength (approx. 2018) and the original brand Estratab is already discontinued

FDA Label Update: Clinical Implications

The November 2025 removal of the black box warnings for cardiovascular disease, breast cancer, and probable dementia is clinically significant. The endometrial cancer boxed warning for systemic estrogen-alone products in women with an intact uterus was retained. Key prescribing implications:

Progestin co-administration remains essential for patients with an intact uterus — this has not changed

The benefit-risk calculation for most menopausal women (under 60, within 10 years of menopause) is generally favorable — the label change supports initiating therapy more readily

Patient counseling should address the label change directly — some patients may have avoided HRT due to the prior warnings and are newly interested in starting therapy

Available Strengths and Dispensing Guidance

Currently available strengths: 0.3 mg, 0.625 mg, and 1.25 mg. The 0.625 mg strength is the most commonly prescribed and the most reliably sourced. The 0.3 mg and 1.25 mg tablets may face more limited availability at certain locations.

Prescribing recommendations to minimize dispensing barriers:

Write for esterified estrogens (generic) rather than Menest DAW when clinically appropriate — generic availability is generally better and cost is lower

Allow generic substitution unless patient has documented brand-specific reason for Menest brand

If the 1.25 mg strength is unavailable, consider whether two 0.625 mg tablets are clinically appropriate on a case-by-case basis

Therapeutic Alternatives and Dosing Approximations

When Menest is consistently unavailable, the following alternatives represent clinically appropriate substitutions with approximate dose equivalencies:

Conjugated Estrogens 0.625 mg (Premarin) ≈ Esterified Estrogens 0.625 mg (Menest) — Note: not bioequivalent; require new prescription. Premarin oral tablets are generally available; vaginal cream formulation has had supply issues.

Estradiol 1 mg oral ≈ Conjugated Estrogens 0.625 mg ≈ Esterified Estrogens 0.625 mg — Clinical approximation only; verify with individual patient response and monitoring

Transdermal estradiol 0.05 mg/day patch ≈ Conjugated Estrogens 0.625 mg oral — Note: estradiol patches are in widespread shortage; estradiol gel (EstroGel, Divigel) and spray (Evamist) are currently more available

Important: These equivalencies are clinical approximations and not FDA-recognized bioequivalence designations. Individual patient response should guide dosing adjustments. When switching from oral to transdermal estrogen, reassess after 4–8 weeks.

Managing Patients with Intact Uterus During a Switch

When transitioning a patient from Menest to an alternative estrogen, ensure the progestin component of their regimen is also evaluated and appropriately adjusted. The type of progestin and dosing schedule may need to change depending on the new estrogen formulation and route. For example, switching from oral to transdermal estrogen may affect the progestin dose threshold needed to protect the endometrium.

Pricing and Patient Assistance

For patients who are struggling with cost:

Generic esterified estrogens 0.625 mg: approximately $86 for 30 tablets with a GoodRx coupon

Brand Menest: $92+ retail; covered as Tier 2–3 on most commercial and Medicare Part D plans

Patient assistance: Pfizer RxPathways program (for Menest brand), Prescription Hope ($70/month), PAN Foundation, and NeedyMeds

Helping Patients Locate Menest in Stock

When patients cannot locate Menest at their pharmacy, direct them to use medfinder for providers — a service that calls pharmacies near the patient to identify which ones have their medication in stock, then texts them the results. This saves patients significant time and your clinical staff from fielding pharmacy-search calls.

See also: How to Help Your Patients Find Menest in Stock: A Provider's Guide.